Researchers say the finding highlights the need for more evidence and better conversations about risks and benefits of mindfulness, yoga, tai chi, acupuncture, and other complementary health approaches.

25 Apr 2026

Yōni.Fit expands use for menstrual discharge management

Watkins-Conti Products, Inc. ("Watkins-Conti"), a company that develops innovative solutions for women's pelvic health, today announced the Company has added a second indication for its flagship product, the Yōni.Fit Bladder Support ("Yōni.Fit").

24 Apr 2026

American Heart Association backs innovators advancing equitable health solutions

Cardiovascular disease remains the leading cause of death in the United States and drives nearly $415 billion in annual health‑related costs, according to the American Heart Association, highlighting the need for scalable, real‑world health innovation.

24 Apr 2026

Elevated Lp(a) levels associated with residual cardiovascular risk

New data analyzing more than 20,000 patients from three major NIH studies show that elevated Lipoprotein(a) [Lp(a)] is associated with residual cardiovascular risk and warrants aggressive risk reduction.

24 Apr 2026

Elite footballers show ancestry-related differences in cardiovascular evaluation

Elite footballers of Black ethnicity show important ancestry-related differences in cardiac adaptation.

24 Apr 2026

Preliminary model developed to improve cardiovascular risk prediction in Latin America and the Caribbean

A preliminary model to improve the prediction of cardiovascular risk in Latin America and the Caribbean was presented today at ESC Preventive Cardiology 2026, the annual congress of the European Association of Preventive Cardiology (EAPC), a branch of the European Society of Cardiology (ESC).

24 Apr 2026

Heatwaves and coldwaves linked to increase in major cardiovascular events

Heatwaves and coldwaves are associated with increases in major cardiovascular events that are exacerbated by air pollution.

24 Apr 2026

Algeria eliminates trachoma as a public health problem after decades of effort

The World Health Organization (WHO) has validated Algeria as having eliminated trachoma as a public health problem, making it the 10th country in WHO's African Region and the 29th country globally to achieve this significant milestone.

24 Apr 2026

Study highlights the fragility of measles elimination in the United States

A new study examined measles vaccination coverage following a large postelimination outbreak, primarily affecting unvaccinated children. Findings from the study will be presented during the Pediatric Academic Societies (PAS) 2026 Meeting, taking place April 24-27 in Boston.

24 Apr 2026

Real-time CGM transforms blood glucose management in type 2 diabetes

A major clinical trial has found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults living with type 2 diabetes who are treated with basal insulin.

23 Apr 2026

U.S. dentists still prescribe opioids at higher rates globally

People getting their teeth pulled or drilled by dentists in the United States are still much more likely to get powerful opioid medications than dental patients in other developed countries or even the U.S. territory of Puerto Rico, a new study finds.

23 Apr 2026

Washington’s hepatitis C elimination initiative improves treatment access, reduces costs

It took less than 22 years after the discovery of the hepatitis C virus (HCV) for a fast-acting, highly effective treatment to become available.

23 Apr 2026

Study highlights gaps in opioid use disorder care during pregnancy

Opioid use disorder during pregnancy remains a critical yet under-addressed public health issue in the U.S., according to a new study at Columbia University Mailman School of Public Health.

23 Apr 2026

APOLLO AI learns from 25 billion medical events to predict future disease

APOLLO is a multimodal temporal foundation model trained on 25.2 billion medical events from 7.2 million patients across 33 years of Mass General Brigham records, integrating 28 medical modalities into unified “virtual patient representations.” Across 322 downstream tasks, the model showed strong performance in disease prediction, treatment-response stratification, hospital operations, and patient retrieval, supporting the idea of more computable, data-driven medicine.

23 Apr 2026

New study maps early molecular changes in jaw joint osteoarthritis

Temporomandibular joint disorders (TMDs) affect a large portion of the global population and are a common source of chronic jaw pain and difficulty in chewing or speaking.

23 Apr 2026

Poor pain control and consent gaps shape hysteroscopy experiences

Inconsistent care and gender biases in hysteroscopy highlight the urgent need for reforms to address pain management and improve women's healthcare experiences.

23 Apr 2026

Bioengineered chewing gum reduces cancer-linked oral microbes

Researchers led by Henry Daniell of the School of Dental Medicine have shown that extracts from bioengineered chewing gum reduce the levels of three microbes known to be associated with head and neck squamous cell cancer (HNSCC), paving the way for more effective and affordable therapies.

23 Apr 2026

New gene therapy improves hearing in patients with rare genetic deafness

A new international study co-led by investigators from Mass General Brigham and the Eye & ENT Hospital of Fudan University shows that a gene therapy for a rare form of genetic deafness successfully restored hearing in most participants, with results lasting up to 2.5 years.

23 Apr 2026

Paxlovid speeds recovery but does not reduce severe COVID outcomes in vaccinated adults

Paxlovid (nirmatrelvir-ritonavir) does not reduce hospital admissions or deaths in vaccinated adults at higher risk of severe COVID-19, despite helping them recover faster, according to results from two national trials published today in the New England Journal of Medicine.

22 Apr 2026

Tirzepatide vs. semaglutide: Study compares cost and health outcomes in obesity

In a US societal-perspective lifetime simulation based on SURMOUNT-5 data, tirzepatide was projected to deliver lower total costs and better health outcomes than semaglutide for adults with obesity or overweight without type 2 diabetes.

22 Apr 2026